Precision Health Research, Singapore (PRECISE), and AI & digital transformation company, Temus, have signed a memorandum of understanding to establish a PRECISE-Temus Joint Innovation Centre (JIC), a five-year collaboration to support the technology, data, and delivery capabilities for Phase III of Singapore’s National Precision Medicine (NPM) programme.
The JIC brings together PRECISE’s leadership of Singapore’s national precision medicine programme with Temus’s vision-to-value with velocity approach to transformation. It will help translate precision medicine from research into practical applications by strengthening the digital infrastructure, operating models, and safeguards needed to manage genomic data securely and responsibly.
NPM’s Phase III, launched in November 2025, aims to sequence the genomes of about 10 per cent of Singapore’s local resident population (450,000 residents) – and build evidence on how genomic information can be used responsibly in healthcare at population scale, while continuing to support research into health and disease.
The JIC builds on work that PRECISE and Temus have undertaken together since 2024, providing a proven foundation for the next phase of the partnership. This includes plans to build a secure genomics data infrastructure that handles around 13.6 petabytes of genomic data – scaling to more than 60 petabytes, cutting data-processing timelines from weeks to days, and generating genome-wide association results for 100,000 genomes. The work spans data pipelines, research platforms, and visualisation solutions.
In partnership with PRECISE, Temus plans to explore talent development pathways for specialist consultants and engineers in areas such as computational biology and bioinformatics specific to precision medicine and genomics.
